218 results about "CD38" patented technology

The invention relates to an anti-CD3 nano antibody, an anti-CD38 antibody and a bispecific antibody containing the anti-CD3 nano antibody and the anti-CD38 antibody. According to the invention, an anti-CD3 nano antibody and an anti-CD38 monoclonal antibody are excavated and prepared, humanized design is carried out to obtain antibodies with high affinity and specificity, and different configurations of bispecific T cell conjugation antibodies targeting CD3 and CD38 are further designed, so that the CD3 and CD38 dual-specificity T cell conjugation antibodies are obtained. The antigen binding activity, the T cell-mediated tumor cell killing effect and the T cell proliferation and activation function of the antibody are systematically evaluated in vitro, and experimental results show that the T cell conjugation antibody can effectively recruit and activate T cells and has a remarkable killing effect on CD38 positive tumor cells, and it is further verified that the antibody has remarkable in-vivo anti-tumor activity and has a good application prospect. Therefore, the polypeptide has high affinity, good pharmacological characteristics and development potential.

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The invention discloses a method for constructing a differential diagnosis model for lupus nephritis and membranous nephropathy, and belongs to the technical field of intelligent medical treatment. The modeling method comprises the following steps: S1, respectively collecting flow cytometry detection data of lupus nephritis patients and healthy control personnel; s2, performing data cleaning and conversion on the flow cytometry detection data, and converting non-numerical features into digits; carrying out implication on the missing value by adopting a k nearest neighbor algorithm from an implication packet; s3, random sampling is carried out on the cleaned and converted data set, and samples are divided into a training set and a verification set according to the proportion of 7: 3; s4, dividing a training subset and a test set from the training set, and iteratively selecting the types of cells incorporated into the constructed model as pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T, and CD38 + PD-1 + CD8T by adopting an RFE method, wherein the types of the cells incorporated into the constructed model are pDC, CD4T, effector CD4T, Th2, CD8T, CD38 + HLA-DR + CD8T and CD38 + PD-1 + CD8T; and S5, performing a classification task by adopting TabPFNClassifier, performing training from features selected from the training data set, then evaluating the performance of the model, performing model training by utilizing detection data, and performing evaluation to construct a lupus nephritis prediction model with high accuracy.

The present invention relates to treatment of IgE-mediated disease with antibodies that specifically bind CD38.

The invention discloses an antibody combination and a system for detecting leukemia stem cells. The antibody combination comprises a CD7 antibody, a CD371 antibody, a CD34 antibody, a CD45RA antibody, a CD123 antibody, a CD133 antibody, a CD38 antibody, a CD45 antibody, a CD90 antibody, a CD33 antibody and a CD19 antibody. The antibody combination provided by the invention can accurately identify target cells and distinguish normal HSCs and pluripotent progenitor cells in a CD34 + CD38-cell population, and the specific antibody has abnormal expression or expression intensity change, so that leukemia stem cells can be rapidly, simply and conveniently detected with high accuracy, high sensitivity and high specificity, the sensitivity of MRD evaluation is favorably improved, and the kit has a good application prospect. Therefore, signs of disease recurrence can be found earlier, more information about disease prognosis can be provided, and doctors and patients can be helped to better understand disease prognosis and possible results.

The embodiment of the invention relates to the technical field of drug detection, in particular to an anti-CD38 antibody drug receptor occupation detection method and system, a peripheral blood sample is used for preparing a single-cell suspension, the single-cell suspension is divided into a TEST tube and an FMO tube, a cell surface antibody and an RO detection antibody are added into the TEST tube, only the cell surface antibody is added into the FMO tube, and only the RO detection antibody is added into the FMO tube. The TEST tube and the FMO tube are subjected to sample detection analysis, so that the average fluorescence intensity of RO detection antibodies of the TEST tube and the FMO tube is obtained. And performing RO detection analysis by adopting a dissociation method, taking the tubes which are not combined with the medicine as a total receptor group, taking the tubes which are combined with the medicine as a dissociation receptor group, and calculating an RO detection result according to the average fluorescence intensity of the TEST tube and the FMO tube.

The present invention relates to treatment of IgE-mediated disease with antibodies that specifically bind CD38.

The present invention relates to compositions comprising NAD and, in some preferred embodiments, further comprising a CD38 inhibitor, an antioxidant, an endogenous cellular health molecule and / or a sirtuin activator as adjuncts. The present invention also relates to pharmaceutical compositions, dosage forms and methods for NAD delivery and supplementation.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-CD38 nano antibody as well as a preparation method and application thereof. The method comprises the following steps: constructing and expressing CD38 antibody protein, immunizing alpaca, obtaining immune alpaca PBMC (peripheral blood mononuclear cells), extracting RNA (ribonucleic acid) of the cells, carrying out reverse transcription to obtain cDNA (complementary deoxyribonucleic acid), carrying out PCR (polymerase chain reaction) to obtain antibody gene segments, constructing the antibody gene segments on a phage expression vector to construct a CD38 immune antibody library, carrying out two rounds of panning, carrying out Clone ELISA (enzyme-linked immuno sorbent assay) detection on clones to obtain an antibody combined with the CD38 protein, carrying out sequencing analysis, and selecting a unique sequence. High-throughput expression is carried out through a mammalian cell high-throughput expression system, antibody protein is obtained, FACS detection is carried out through a CD38 high-expression cell line, and finally the antibody combined with CD38 is obtained. The method is simple and rapid to operate, a mammalian cell expression system induces efficient expression of the antibody, processing modification can be performed after translation, and the activity of the antibody is closer to that of a natural antibody.

The invention discloses a lupus nephritis marker and application thereof, and belongs to the technical field of biomarkers. The marker for the lupus nephritis, disclosed by the invention, comprises one or more of CD8, CD38 and PD-1. By detecting specific cell surface markers in patient blood, early diagnosis of LN is assisted in a minimally invasive mode, and based on deep comparative analysis of LN patients and healthy people, the specificity and sensitivity of the biomarkers in LN diagnosis are ensured through screening of the biomarkers. In the aspect of differential diagnosis, a clinician is assisted to distinguish LN from other types of kidney diseases, such as membranous nephropathy (MN) and anti-neutrophil cytoplasm antibody related vasculitis (AAV), by analyzing specific biomarker modes of different nephropathy. The dependence on kidney puncture is reduced, related potential risks and inconvenience are avoided, and meanwhile more accurate and timely diagnosis is provided for an SLE patient.

Genetically engineered cells (e.g., HSPCs or T cells) having one or more genetically edited cell surface protein genes, such as hematopoietic stem cells, and therapeutic uses thereof, alone or in combination with immunotherapy targeting the cell surface proteins.

The application relates to quinoline and quinazoline carboxamide derivatives of the general formula (I) that have activity as cluster of differentiation 38 (CD38) inhibitors, and to pharmaceutical compositions comprising such compounds. The compounds are useful for preventing or treating diseases and disorders such as, for example, diseases and disorders of metabolism.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

Multispecific antibodies with reduced isoelectric focusing points are described herein.

The present disclosure provides compounds, in part, compounds of Formula I or Formula II, and their use in the treatment of medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making the compounds of the present disclosure are provided. These compounds are envisaged to be modulators, e.g., inhibitors, of cyclic ADP ribohydrolase (CD38).

The invention discloses an antibody for inhibiting interference of a CD38 monoclonal antibody on transfusion compatibility detection, a heavy chain amino acid sequence of the antibody is shown as a sequence 1, and a light chain amino acid sequence of the antibody is shown as a sequence 2. The anti-human CD38 rabbit monoclonal antibody is adopted and can be effectively combined with the CD38 antigen on the surface of human red blood cells, so that the combination of the human CD38 monoclonal antibody and the CD38 antigen is inhibited.

Provided is an antibody capable of specifically binding to CD38, or an antigen-binding portion thereof. Also provided is a recombinant fusion protein, comprising: i) a CD38 antibody or an antigen-binding portion thereof; and ii) a CD47 binding peptide, wherein the CD47 binding peptide is linked to an N-terminus of a heavy chain or light chain of the CD38 antibody or the antigen-binding portion thereof, and the CD47 binding peptide is an extracellular Ig-like domain of a signal regulatory protein (SIRP).

The invention discloses a diagnostic marker for ANCA (Angiovasculitis) related vasculitis. It is found for the first time that the CD19 + CD38 + CD27-CD24 + cell can be used as the diagnosis marker of ANCA related vasculitis, and the diagnosis efficiency is high; in addition, it is found that the CD19 + CD38 + CD27-CD24 + cells can remarkably distinguish ANCA related vasculitis and membranous nephropathy or ANCA related vasculitis and lupus nephritis, a new direction is provided for diagnosis and subsequent treatment of ANCA related vasculitis, and the application has wide application prospects clinically.

The invention provides application of ganoderma lucidum ketone A in preparation of a CD38 inhibitor and related products. The ganoderma lucidum ketone A is applied to preparation of the CD38 inhibitor. The problem of limitation of a CD38 inhibitor in the prior art can be solved, and the CD38 inhibitor is suitable for the field of biochemistry.

Provided is an antibody capable of specifically binding to CD38, or an antigen-binding portion thereof. Also provided is a recombinant fusion protein, comprising: i) a CD38 antibody or an antigen-binding portion thereof; and ii) a CD47 binding peptide, wherein the CD47 binding peptide is linked to an N-terminus of a heavy chain or light chain of the CD38 antibody or the antigen-binding portion thereof, and the CD47 binding peptide is an extracellular Ig-like domain of a signal regulatory protein (SIRP).

Provided herein are, inter alia, novel peptide compositions having bi-specific binding capabilities useful for therapeutic and diagnostic purposes. The peptide compositions provided herein are polypeptide conjugates including at an anti-CD3 binding domain and a CD38 binding domain and are therefore able to target (bind) CD3 and CD38 at the same time. The peptide compositions provided herein are highly efficient binders and can be produced at very high yields and are therefore easy to manufacture.

Disclosed herein is a genetically engineered cells expressing a chimeric antigen receptor and methods and uses thereof.

The invention belongs to the technical field of biology, and discloses an anti-human CD38 antibody and application thereof. The anti-human CD38 antibody disclosed by the invention can be specifically combined with human CD38 protein, and the combination is stable. The antibody is coupled with an adsorption column to pertinently adsorb B cells in blood, so that the level of pathogenic factors can be quickly reduced, and abnormally activated or pathogenic B cells in circulation and pathogenic factors such as antibodies, cell factors and the like generated by the abnormally activated or pathogenic B cells are quickly reduced, thereby quickly relieving symptoms. The B cells can be cleared relatively specifically, and the influence on other cells is reduced. The traditional Chinese medicine composition has the advantages that time is bought for other treatments, in the acute attack or serious stage of diseases, illness state stabilization is facilitated, favorable conditions are created for subsequent immunoregulation treatment or other targeted treatment, immune imbalance can be improved, the imbalance state of an immune system can be adjusted, and immune homeostasis can be recovered. When necessary, adsorption can be repeatedly carried out to maintain the treatment effect, and the safety is high.

Disclosed herein are engineered natural killer cells that have been modified to express chimeric antigen receptors (CARs). The cells optionally contain other modifications that improve tumor specific cytotoxicity and homing to tumor sites. Also contemplated are methods for using the engineered natural killer cells to treat patients with cancer.

Provided herein are methods of making tumor reactive peripheral blood lymphocytes (trPBLs) using PBMCs obtained from a patient. The method comprises enriching trPBLs from PBMCs using markers that are expressed or secreted by the trPBLs, such as 4- IBB, CD103, CXCL13, IFN-y, CXCR6, CD200, HLA-DR, CD69, PD-1, CD39, CD38, CD49a, etc. Further provided are use of the trPBLs or pharmaceutical compositions thereof for the treatment of cancers.

The present disclosure provides compounds, in part, compounds of Formula I or Formula II, and their use in the treatment of medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making the compounds of the present disclosure are provided. These compounds are envisaged to be modulators, e.g., inhibitors, of cyclic ADP ribohydrolase (CD38).

Disclosed in the present invention are a polysubstituted aminoquinoline compound and the use thereof. Specifically disclosed in the present invention is a compound as represented by formula (I), or a stereoisomer, tautomer, crystal form, pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof. The compound of the present invention is a CD38 inhibitor, and can be used in the preparation of a drug for treating and / or preventing diseases related to abnormal expression or activity of CD38.

CD38 is also expressed in a variety of hematological malignancies, including multiple myeloma. In the present invention, the inventors obtained a new antibody against CD38 that can be used to produce bispecific antibodies and CAR T cell populations. In particular, the inventors reported the development of Bi38-3, a new bispecific T cell engager that targets CD38 on MM cells and forms cytotoxic T cells through CD3ε. Bi38-3 lacks the Fc region of natural mAbs, which contributes to the resistance process, but triggers T cell proliferation, cytokine release, and lysis of CD38-positive MM cells in vitro. Similarly, Bi38-3 induces autologous T cells to eliminate tumor plasma cells isolated from MM patients at diagnosis and relapse. The cytotoxicity triggered by Bi38-3 is limited to cells expressing high levels of CD38 and maintains the integrity of T, B, and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in the MM1.S xenograft mouse model of human MM. In summary, the results show that the antibody of the present invention is an effective agent for specifically eliminating CD38-positive malignant cells without significantly affecting CD38-low-expressing cells, and is a promising new immunotherapy tool for treating malignant blood diseases, especially multiple myeloma.

The invention discloses a targeted multi-channel synergistic anti-aging composition as well as a preparation method and application thereof, and belongs to the technical field of functional foods and biological medicines. According to the composition disclosed by the invention, ginsenoside, a hawthorn polyphenol-chitosan phospholipid complex and spina date seed total saponins are taken as core active ingredients, and a specific Senlytics active ingredient and a natural mTOR inhibitor are compounded, so that the synergistic regulation of five anti-aging pathways, namely Sirtuins activation, mTOR inhibition, mitochondrial autophagy activation, CD38 inhibition and senescent cell removal, can be realized at the same time. The composition is natural in raw material source, high in safety and good in stability, can be prepared into various dosage forms such as capsules, solid beverages and oral liquid, is suitable for daily anti-aging and sub-health conditioning, and has wide application prospects in the fields of anti-aging health foods and biological medicines.